The technique of using drugs to target latent virus reservoirs has been introduced to reawaken dormant viruses such that the immune system can attack them, but further tests have shown this method fails. In this study, the author attempted to mathematically analyze whether drugs can be used to reawaken dormant virus reservoirs and proposed the use of viral proteins to activate the sleeping virus. The results show that the amino acid sequence ARG of Gag proteins of HTLV1, HTLV2, STLV1 and STLV2 match their primer binding site GGGGGCTCG in the 3'-to-5' direction and that the amino acid sequence SPR of Gag proteins of HIV1, HIV2, SIV and FIV match their primer binding site GGCGCCCGA in the 3'-to-5' direction. The author hence believes that the latency-reversing drugs are involved in the process of the transcription of cancer genes, and because the virus genome they reawaken contains the same NF-κB binding sites, the drugs indirectly reawaken dormant retrovirus infection. A related study showed that the genomic Gag/Gag-Pol complex recruits the LysRS/tRNA complex. The selective packaging of the tRNA primer requires HIV-1 Gag and Gag-Pol, and an interaction between LysRS and Gag is observed in vitro. In contrast, Gag proteins can more reliably be used to directly reawaken dormant HIV infection, which recruits human uncharged tRNA to serve as the reverse transcription primer.